This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (94)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Evidence-Based Medicine  • Alert me on articles by topic

Current Perspectives and Future Needs

Timothy Brewer, MD, MPH; Graham A. Colditz, MD, DrPH

JAMA. 1999;281:824-829.

Spontaneous reporting systems like MEDWATCH can be effective in revealing unusual or rare adverse events that occur with the use of medications, and such reports may often be sufficient to assign causality. However, spontaneous reports do not reliably detect adverse drug reactions (ADRs) that occur widely separated in time from the original use of the drug or that represent an increased risk of an adverse event that occurs commonly in populations not exposed to the drug. In these situations, spontaneous reports alone do not provide sufficient evidence to conclude that the adverse event was an ADR. Identification of ADRs associated with long-term administration of drugs for chronic diseases also remains problematic. Methods to evaluate ADRs using data from clinical trials, medical records, and computerized databases of medication users and nonusers must be developed to complement spontaneous reporting systems. Without these methods, potentially important ADRs will remain undetected, and spurious associations between adverse outcomes and medications or devices will remain unchallenged.

Author Affiliations: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School (Drs Brewer and Colditz), and Technology Assessment Group, Harvard School of Public Health (Dr Colditz), Boston, Mass.

RELATED ARTICLES

The Role of Meta-analysis in the Regulatory Process for Foods, Drugs, and Devices
Jesse A. Berlin and Graham A. Colditz
JAMA. 1999;281(9):830-834.
ABSTRACT | FULL TEXT  

Meta-analysis and Epidemiologic Studies in Drug Development and Postmarketing Surveillance
Robert Temple
JAMA. 1999;281(9):841-844.
EXTRACT | FULL TEXT  

March 3, 1999
JAMA. 1999;281(9):863-864.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Safety Monitoring of Drugs Receiving Pediatric Marketing Exclusivity
Smith et al.
Pediatrics 2008;122:e628-e633.
ABSTRACT | FULL TEXT  

Meta-Analysis
Cleophas and Zwinderman
Circulation 2007;115:2870-2875.
FULL TEXT  

POSTMARKETING MODIFICATIONS IN THE SAFETY LABELING OF THE NEW ANTIEPILEPTICS
Buck et al.
Neurology 2007;68:1536-1537.
FULL TEXT  

Management of children with idiopathic short stature
Dunkel
Eur J Endocrinol 2006;155:S35-S38.
ABSTRACT | FULL TEXT  

Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials
Zhang et al.
JAMA 2006;296:1619-1632.
ABSTRACT | FULL TEXT  

Combined Estrogen and Testosterone Use and Risk of Breast Cancer in Postmenopausal Women
Tamimi et al.
Arch Intern Med 2006;166:1483-1489.
ABSTRACT | FULL TEXT  

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
Schiff et al.
Ann Rheum Dis 2006;65:889-894.
ABSTRACT | FULL TEXT  

Re-examining our approach to the approval and use of new drugs.
Lee
CMAJ 2006;174:1855-1855.
FULL TEXT  

Swedish registers to examine drug safety and clinical issues in RA
Askling et al.
Ann Rheum Dis 2006;65:707-712.
ABSTRACT | FULL TEXT  

Autologous Cultured Chondrocytes: Adverse Events Reported to the United States Food and Drug Administration
Wood et al.
JBJS 2006;88:503-507.
ABSTRACT | FULL TEXT  

Using data from automated dispensing units to identify adverse drug reactions
McIntosh and Petropoulos
Am J Health Syst Pharm 2005;62:2397-2400.
FULL TEXT  

Safety and Efficacy of Growth Hormone Treatment for Idiopathic Short Stature
Cuttler
J. Clin. Endocrinol. Metab. 2005;90:5502-5504.
FULL TEXT  

Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura
Gaines
Blood 2005;106:1532-1537.
ABSTRACT | FULL TEXT  

The Research on Adverse Drug Events and Reports (RADAR) Project
Bennett et al.
JAMA 2005;293:2131-2140.
ABSTRACT | FULL TEXT  

Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
Feltelius et al.
Ann Rheum Dis 2005;64:246-252.
ABSTRACT | FULL TEXT  

Recent developments in gene transfer: risk and ethics
Kimmelman
BMJ 2005;330:79-82.
FULL TEXT  

Postmarketing Surveillance--Lack of Vigilance, Lack of Trust
Fontanarosa et al.
JAMA 2004;292:2647-2650.
FULL TEXT  

Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project
Ladewski et al.
JCO 2003;21:3859-3866.
ABSTRACT | FULL TEXT  

Making the Case for a Qualitative Study of Medical Errors in Primary Care
Kuzel et al.
Qual Health Res 2003;13:743-780.
ABSTRACT  

Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
Kwon et al.
ANN INTERN MED 2003;138:807-811.
ABSTRACT | FULL TEXT  

Sildenafil for Male Erectile Dysfunction: A Systematic Review and Meta-analysis
Fink et al.
Arch Intern Med 2002;162:1349-1360.
ABSTRACT | FULL TEXT  

Timing of New Black Box Warnings and Withdrawals for Prescription Medications
Lasser et al.
JAMA 2002;287:2215-2220.
ABSTRACT | FULL TEXT  

Evidence in Upheaval: Incorporating Observational Data Into Clinical Practice
Ray
Arch Intern Med 2002;162:249-254.
FULL TEXT  

Changing the Status of Drugs from Prescription to Over-the-Counter Availability
Brass
NEJM 2001;345:810-816.
FULL TEXT  

Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality
Paradiso-Hardy et al.
CMAJ 2000;163:1441-1448.
ABSTRACT | FULL TEXT  

Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rho(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients
Gaines
Blood 2000;95:2523-2529.
ABSTRACT | FULL TEXT  

Meta-analysis and Epidemiologic Studies in Drug Development and Postmarketing Surveillance
Temple
JAMA 1999;281:841-844.
FULL TEXT